Latest Breaking News On - Slower infusion - Page 1 : comparemela.com

A patient in a phase 2 trial has received the first dose of a novel combination of botensilimab and balstilimab plus agenT-979, an allogeneic cell therapy.

United statesJennifer buellYelena janjigianGastrointestinal oncology serviceAmerican cancer societyMemorial sloan kettering cancer centerMink therapeuticsAmerican cancerChief gastrointestinal oncology serviceVitrakvi continuesImprove survivalSlower infusionAntiemetic drugs may help with nauseaGastric cancerAgent 797Phase 2 trial